With these key hires, Alpha Cognition is poised to advance its mission of improving the lives of patients and families ...

Alpha Cognition (ACOG) announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; ...

Alpha Cognition Inc. (NASDAQ:ACOG) and China Medical System Holdings Limited announced an exclusive licensing agreement for ...

Anavex's financial health is stable with cash runway into 2028, but rising expenses are expected. Click here to find out why ...

VANCOUVER, British Columbia & DALLAS, January 08, 2025--Alpha Cognition, Inc. (Nasdaq: ACOG) ("ACI" or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating ...

Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Collaboration and Distribution Agreement (the “Agreement”) with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or ...

The agreement with China Medical System Holdings Limited is for the development, manufacturing, and commercialization of ...